Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200035/S041

OrganOx metra System

Organox Limited · Decision date Aug 7, 2026

FDA DECISIONP200035/S041

What did the FDA decide?

FDA records P200035/S041 as a supplement to PMA P200035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 7, 2026.

FDA approval order statement

approval for revalidation of the endotoxin (LAL) test method of the Sodium Taurocholate/Bile Salts (C0364) component of the D0146/D0146-US Disposable Set
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Aug 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200035/S041
Regulatory pathway
PMA supplement
Product code
QQK
Decision code
OK30
Decision date
Aug 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation.

Product code
QQK
FDA device class
3

For the original device and its historical approval scope, see PMA P200035. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200035 · Original PMA

    OrganOx metra System

  2. P200035/S041 received

    Application receipt date recorded by FDA.

  3. P200035/S041 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P200035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200035

Product / regulatory recordCompanyPathwayDecision dateSource
Organox LimitedPMA approvalDec 9, 2021FDA
Organox LimitedPMA supplementJul 18, 2025FDA
Organox LimitedPMA supplementAug 20, 2025FDA
Organox LimitedPMA supplementAug 22, 2025FDA
Organox LimitedPMA supplementAug 28, 2025FDA
Organox LimitedPMA supplementSep 8, 2025FDA
Organox LimitedPMA supplementSep 19, 2025FDA
Organox LimitedPMA supplementDec 17, 2025FDA
Organox LimitedPMA supplementMar 16, 2026FDA
Organox LimitedPMA supplementMar 30, 2026FDA
Organox LimitedPMA supplementApr 10, 2026FDA
Organox LimitedPMA supplementMay 21, 2026FDA
Organox LimitedPMA supplementJun 5, 2026FDA
Organox LimitedPMA supplementJul 7, 2026FDA
Organox LimitedPMA supplementJul 8, 2026FDA
Organox LimitedPMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code QQK

Product / regulatory recordCompanyPathwayDecision dateSource
TransMedics, Inc.PMA supplementMay 13, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Organox Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Oxford Science Park, Magdalen Centre, Robert Robinson Ave., Oxford, OX4 4GA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records